Report Overview

2023

Base Year

2018-2023

Historical Year

2024-2032

Forecast Year

North America Hemoglobinopathies Market Analysis

Hemoglobinopathies are a group of inherited disorders characterized by the abnormal structure or production of the hemoglobin molecule. Sickle cell anemia and thalassemia are some common types of hemoglobinopathies. In the United States, around 100,000 individuals are affected by sickle cell disease. It is highly prevalent in African Americans, occurring in 1 out of every 365 African American births. The rising prevalence of sickle cell anemia disease is expected to increase demand for effective treatment options, driving North America hemoglobinopathies market growth.

 

One of the major market trends is the development of novel therapies to combat the growing cases of hemoglobinopathies. Furthermore, the rise in regulatory approvals by health regulatory bodies including United States Food and Drug Administration (FDA) to address the unmet of clinical needs of a large patient base is likely to boost market size in the region. In December 2023, the FDA granted approval to the first cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease (SCD) in patients aged 12 years and more. Such innovations along with their high acceptance rate is projected to augment the North America hemoglobinopathies market share in the forecast period.

 

Casgevy, developed by Vertex Pharmaceuticals Incorporated, and a Swiss–American biotechnology CRISPR Therapeutics AG, is the first FDA-approved CRISPR/Cas9 therapy for the treatment of sickle cell disease in patients with recurrent vaso-occlusive crises. On the other hand, Bluebird Bio, Inc.’s Lyfgenia is a cell-based gene therapy that utilizes a lentiviral vector for gene delivery. It is used for the treatment of sickle cell disease in patients showing a history of vaso-occlusive events. The approval of these novel gene therapies which have the potential to cure the inherited disease is anticipated to fuel the North America hemoglobinopathies market demand.

 

The market is also driven by increased investments from both government and private sectors to support research activities aimed at the advancement of diagnostic methods and treatment of hemoglobinopathies. For instance, in July 2023, the National Institutes of Health awarded a USD 2.6 million grant to a Rice University bioengineer and his research team. The 4-year grant was intended to be used in investigating the efficacy and safety of gene editing technology to treat sickle cell disease. The rise in funding will help in the development of new treatment therapies which will propel the market growth in the region.

 

North America Hemoglobinopathies Market Report Snapshots

North America Hemoglobinopathies Market Size

North America Hemoglobinopathies Market Analysis

North America Hemoglobinopathies Companies

 

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market is anticipated to grow at a CAGR of 5.10% during the forecast period of 2024-2032, driven by the growing prevalence of sickle cell anemia and thalassemia in the region.

The rising advancements in the treatment and diagnostics of hemoglobinopathies are fuelling the demand for the market.

One of the significant trends in the market is the rise in regulatory approvals by the health regulatory body United States Food and Drug Administration (FDA). In December 2023, Casgevy and Lyfgenia, the first cell-based gene therapies received FDA approval for the treatment of sickle cell disease (SCD) in patients aged 12 years and more.

Based on the diagnosis, the market is segmented into red blood cell (RBC) count test, genetic testing, high performance liquid chromatography (HPLC) test, hemoglobin isoelectric (Hb IEF) focusing, hemoglobin electrophoresis (Hb ELP) test, and hemoglobin solubility test.

Treatments available in the market include allogeneic stem cell therapy, autologous stem cell therapy, and syngeneic stem cell therapy.

By type, the market is divided into thalassemia, and sickle cell disease, among others.

The market breakup by therapy includes monoclonal antibody medication, ace inhibitors, and hydroxyurea, among others.

End users of the market are biopharmaceutical & biotechnology companies, academic & research institutes, among others.

Major distribution channels of the market include hospital pharmacies, online providers, drug stores, and retail pharmacies, among others.

The market segmentation by countries includes the United States of America and Canada.  

The key players in the market are Sangamo Therapeutics, Inc., Global Blood Therapeutics, Bluebird bio, Inc., Emmaus Life Science Inc., Pfizer, Inc., Novartis AG, Prolong Pharmaceuticals, LLC, Bioverativ Inc., Gamida Cell, and Celgene Corporation.

Purchase Full Report

Datasheet

 

USD 2,639

USD 2,399

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 4,399

USD 3,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 5,829

USD 5,299

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 6,929

USD 6,299

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

$getforecastarray = array(); if (isset($ismapshow)) { $forecast_period_start = isset($forecast_period_start) ? $forecast_period_start : ''; if ($forecast_period_start != "") { $yearInc = 1; for ($startfrom = $forecast_period_start; $startfrom <= $forecast_period_end; $startfrom++) { $calculatFercastYear = calculateFutureValue(($getReportDetail['base_value'] > 0) ? $getReportDetail['base_value'] : 100, $getReportDetail['cagr'], $yearInc); $getforecastarray[] = array('years' => "$startfrom", 'value' => $calculatFercastYear); $yearInc++; } } } $getforecastarrayJson = json_encode($getforecastarray); ?>